 |
|
| Type | Public (NASDAQ: AMLN) |
|---|---|
| Founded | 1987 |
| Headquarters |  San Diego, California, USA |
| Key people | Daniel M. Bradbury[1] |
| Industry | Biotechnology |
| Products | Symlin (pramlintide) Byetta (exenatide) |
| Employees | 1,900 [1] |
| Website | www.amylin.com |
Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces two drugs, Symlin (pramlintide acetate) and Byetta (exenatide). Amylin also is working on producing a drug based on Leptin.[2].
References
- ^ "Company Profile for Amylin Pharmaceuticals Inc (AMLN)". http://www.zenobank.com/index.php?symbol=AMLN&page=quotesearch. Retrieved on 2008-10-21.
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
